Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?
By the Top Tier Newswire AI Desk · August 6, 2026 at 12:15 AM ET · reviewed against 8 wire stories
TWIST BIOSCIENCE COR (TWST) is up +15.65% in the latest session. Our newswire has captured 8 stories on TWST across 5 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
TWST stock surged 15.65% to $115.01 on Tuesday, driven primarily by the company's announcement of an upsized $300 million public offering. The offering, priced at $96 per share for 3.125 million shares, is intended to fund R&D and manufacturing expansion. The move comes amid recent regulatory filings and renewed investor interest in the firm's growth strategy.
What Happened
Twist Bioscience filed an 8-K with the SEC on August 5, disclosing a material definitive agreement and additional financial details. The company also announced the pricing of its upsized public offering, with shares set to close on August 6. The offering was upsized from an initial $250 million proposal and includes an option for underwriters to purchase additional shares. This expansion of capital raises expectations for increased R&D and production capabilities. The offering price of $96 per share represents a significant discount to the stock's current price, contributing to investor optimism.
What The Data Shows
Over the past eight sessions, TWST has gained 32.9%, rising from $86.54 to $115.01. The stock has traded within a 52-week range of $23.30 to $106.58, suggesting this move extends beyond typical volatility. The company's fundamentals remain unprofitable, with a trailing twelve-month net margin of -31.7% and earnings per share of -2.23. Despite this, revenue is growing at 19.2% year-to-date. Recent insider transactions show three executives sold shares totaling $14.8 million in the last 90 days, with the most recent sales occurring on August 3.
What To Watch
The stock is expected to close the offering on August 6. Investors should monitor the company's upcoming earnings and how the new capital is deployed. The stock's performance in the coming weeks will likely reflect progress in R&D and manufacturing expansion.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TWST · Aug 6 session (5-min) · -6.09% vs prior close · updated 8:44 PM ETAI sentiment, last 36h · averaged over 8 stories · 38/100 bearish
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoSEC 8-KNEUTRAL 50General
Twist Bioscience Corp (TWST) files 8-K
Filed: 2026-08-05 AccNo: 0001104659-26-091280 Size: 558 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
5d agoSeeking AlphaBULLISH 58General
Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety
Twist Bioscience (TWST) is surging in 2026 on AI-enabled drug discovery growth and improving margins, but valuation looks demanding—read the outlook.
5d agoMarketChameleonBEARISH 28General
Twist Bioscience’s $300 Million Upsized Offering Targets Expansion—What Does It Signal for Growth Strategy?
Twist Bioscience has announced an upsized public stock offering, raising $300 million to fuel R&D and manufacturing expansion. This strategic move underlines the company's focus on innovation and growth. Here's a breakdown of the offering details, use of proceeds, and what investors should watch for as Twist positions itself for the future.
5d agoSeeking AlphaBEARISH 24General
Twist Bioscience prices upsized $300M equity at $96 per share
Twist Bioscience (TWST) priced an upsized underwritten public offering of 3.125M common shares at $96.00 per share.
5d agoStockTitanBEARISH 24General
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Shares are priced at $96 each; closing is expected Aug. 6, subject to conditions. Net proceeds are intended for research and manufacturing capacity.
5d agoSeeking AlphaBULLISH 57General
Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells
Conestoga Micro Cap Composite highlights top performers like Twist Bioscience and key portfolio shifts during Q2 2026. Read the full analysis for more details.
6d agoStockTitanBEARISH 24General
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Twist intends to grant underwriters an option for up to an additional $37.5 million in shares; the proposed offering remains subject to market and other conditions.
7d agoYahoo TopBEARISH 38Earnings
Twist Bioscience Shares Decline Following Quarterly Earnings Miss
Twist Bioscience shares fell after the company missed fiscal third-quarter earnings estimates despite reporting stronger-than-expected revenue, as investors remained focused on profitability trends.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →